Outcome | Follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall quality of evidence |
---|---|---|---|---|---|---|---|
Primary outcomes | |||||||
Change in CT score | |||||||
Lund-McKay Score | 16 weeks | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Percent opacification on CT | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Change in clinical polyp score | |||||||
Total nasal endoscopic polyp score | 16 weeks; 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Change in quality of life | |||||||
SF-36 | 16 weeks | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
AQLQ | 16 weeks | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
RSOM-31 | 16 weeks | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
TNSS | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
SNOT-20 | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Secondary outcomes | |||||||
Change in cellular inflammation | |||||||
Eosinophil count (nasal lavage) | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Change in nasal airflow | |||||||
PNIF | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Change in olfaction | |||||||
UPSIT | 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |
Adverse events | 16 weeks; 6 months | Moderate limitation | Not relevant | No serious indirectness | Serious imprecision | Unlikely | Low |